Skip to main content

Table 3 Complications, treatments, and medications in 239 critically ill patients with COVID-19

From: Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China

Characteristics All patients (n = 239) Non-survivors (n = 147) Survivors (n = 92) p value, survivors vs non-survivors
Complications
 ARDS 164 (68.6%) 118 (80.3%) 46 (50.0%) < 0.001
 Acute cardiac injury 103 (43.1%) 81 (55.1%) 22 (23.9%) < 0.001
 AKI 119 (49.8%) 99 (67.4%) 20 (21.7%) < 0.001
 Liver dysfunction 191 (79.9%) 127 (86.4%) 64 (69.6%) < 0.001
 Coagulopathy 150 (62.7%) 111 (75.5%) 39 (42.4%) < 0.001
Hospital-acquired infection
 Bacterial pneumonia 25 (10.5%) 16 (10.9%) 9 (9.8%) 0.484
 Bacteremia 10 (4.2%) 8 (5.4%) 2 (2.2%) 0.187
 Urinary tract infection 5 (2.1%) 4 (2.7%) 1 (1.1%) 0.652
Treatments
 Mechanical ventilation 165 (69.0%) 119 (81.0%) 46 (50.0) < 0.001
  Invasive 79 (33.1%) 71 (48.3%) 8 (8.7%) < 0.001
  Noninvasive 136 (56.1%) 95 (64.6%) 41 (43.6%) 0.002
  Noninvasive + invasive 50 (20.9%) 47 (32.0%) 3 (3.3%) < 0.001
 Extracorporeal membrane oxygenation 9 (3.8%) 9 (6.1%) 0 (0.0%) 0.011
 Renal replacement therapy 12 (5.0%) 11 (7.5%) 1 (1.1%) 0.022
Medications
 Antiviral agents 132 (55.2%) 82 (55.8%) 50 (54.5%) 0.466
  Arbidol 77 (32.2%) 46 (31.3%) 31 (33.7%) 0.776
  Interferon alpha 91 (38.1%) 56 (38.1%) 35 (38.0%) 1.000
  Oseltamivir 59 (24.7%) 32 (21.8%) 27 (29.4%) 0.218
  Lopinavir/ritonavir 38 (15.9%) 24 (16.3%) 14 (15.2%) 0.858
  Ribavirin 13 (5.4%) 6 (4.1%) 7 (7.6%) 0.255
  Ganciclovir 41 (17.2%) 21 (14.3%) 20 (21.7%) 0.159
 Antibacterial agents 229 (95.8%) 144 (98.0%) 85 (92.4%) 0.041
 Methylprednisolon 189 (79.1%) 118 (80.3%) 71 (77.2%) 0.339
  Commutative dosages, median [IQR], mg 360 [200–580] 370 [160–640] 320 [240–580] 0.517
  Dose, methylprednisolon equivalent/days, mg 60.9 ± 21.7 64.6 ± 23.0 54.7 ± 17.9 0.0021
  Duration of methylprednisolon, days 6 [4–10] 6 [3–10] 7 [5–11] 0.0345
 Immunoglobulin 138 (57.7%) 94 (64.0%) 44 (47.8%) 0.010
 Thymosin α1 103 (43.10) 67 (45.6%) 36 (39.1%) 0.199
 Length of ICU stay, median [IQR], days 17 [10–26] 12 [8–18] 26.5 [19–46.5] < 0.001
  1. ARDS acute respiratory distress syndrome, AKI acute kidney injury, IQR interquartile range
  2. Data were expressed as count (%) unless otherwise